Dietary nanoparticles alter the composition and function of the gut microbiota in mice at dose levels relevant for human exposure.


Journal

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
ISSN: 1873-6351
Titre abrégé: Food Chem Toxicol
Pays: England
ID NLM: 8207483

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 27 04 2021
revised: 02 06 2021
accepted: 12 06 2021
pubmed: 22 6 2021
medline: 3 11 2021
entrez: 21 6 2021
Statut: ppublish

Résumé

Nanotechnologies provide new opportunities for improving the safety, quality, shelf life, flavor and appearance of foods. The most common nanoparticles (NPs) in human diet are silver metal, mainly present in food packaging and appliances, and silicon and titanium dioxides used as additives. The rapid development and commercialization of consumer products containing these engineered NPs is, however, not well supported by appropriate toxicological studies and risk assessment. Local and systemic toxicity and/or disruption of the gut microbiota (GM) have already been observed after oral administration of NPs in experimental animals, but results are not consistent and doses used were often much higher than the estimated human intakes. In view of the strong evidence linking alterations of the GM to cardiometabolic (CM) diseases, we hypothesized that dietary NPs might disturb this GM-CM axis. We exposed male C57BL/6JRj mice (n = 13 per dose group) to dietary NPs mixed in food pellets at doses relevant for human exposure: Ag (0, 4, 40 or 400 μg/kg pellet), SiO No overt toxicity was recorded. The GM β-diversity was dose-dependently disrupted by the three NPs, and the bacterial short chain fatty acids (SCFAs) were dose-dependently reduced after the administration of SiO We found that long-term oral exposure to dietary NPs at doses relevant for estimated human intakes disrupts the GM composition and function. These modifications did not appear associated with atheromatous or deleterious metabolic outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Nanotechnologies provide new opportunities for improving the safety, quality, shelf life, flavor and appearance of foods. The most common nanoparticles (NPs) in human diet are silver metal, mainly present in food packaging and appliances, and silicon and titanium dioxides used as additives. The rapid development and commercialization of consumer products containing these engineered NPs is, however, not well supported by appropriate toxicological studies and risk assessment. Local and systemic toxicity and/or disruption of the gut microbiota (GM) have already been observed after oral administration of NPs in experimental animals, but results are not consistent and doses used were often much higher than the estimated human intakes. In view of the strong evidence linking alterations of the GM to cardiometabolic (CM) diseases, we hypothesized that dietary NPs might disturb this GM-CM axis.
MATERIALS AND METHODS METHODS
We exposed male C57BL/6JRj mice (n = 13 per dose group) to dietary NPs mixed in food pellets at doses relevant for human exposure: Ag (0, 4, 40 or 400 μg/kg pellet), SiO
RESULTS RESULTS
No overt toxicity was recorded. The GM β-diversity was dose-dependently disrupted by the three NPs, and the bacterial short chain fatty acids (SCFAs) were dose-dependently reduced after the administration of SiO
CONCLUSION CONCLUSIONS
We found that long-term oral exposure to dietary NPs at doses relevant for estimated human intakes disrupts the GM composition and function. These modifications did not appear associated with atheromatous or deleterious metabolic outcomes.

Identifiants

pubmed: 34153347
pii: S0278-6915(21)00385-9
doi: 10.1016/j.fct.2021.112352
pii:
doi:

Substances chimiques

Fatty Acids, Volatile 0
Interleukin-6 0
Triglycerides 0
interleukin-6, mouse 0
titanium dioxide 15FIX9V2JP
Silver 3M4G523W1G
Silicon Dioxide 7631-86-9
Titanium D1JT611TNE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112352

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Laeticia Perez (L)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium. Electronic address: laeticia.perez@uclouvain.be.

Eleonora Scarcello (E)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium.

Saloua Ibouraadaten (S)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium.

Yousof Yakoub (Y)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium.

Riccardo Leinardi (R)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium.

Jérôme Ambroise (J)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Centre de Technologies Moléculaires Appliquées, Clos Chapelle-aux-champs 30, 1200, Brussels, Belgium.

Bertrand Bearzatto (B)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Centre de Technologies Moléculaires Appliquées, Clos Chapelle-aux-champs 30, 1200, Brussels, Belgium.

Jean-Luc Gala (JL)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Centre de Technologies Moléculaires Appliquées, Clos Chapelle-aux-champs 30, 1200, Brussels, Belgium.

Adrien Paquot (A)

Université catholique de Louvain, Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Avenue Mounier 73, B1.72.01, 1200, Brussels, Belgium.

Giulio G Muccioli (GG)

Université catholique de Louvain, Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Avenue Mounier 73, B1.72.01, 1200, Brussels, Belgium.

Caroline Bouzin (C)

IREC Imaging Platform (2IP), Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.

Sybille van den Brule (S)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium.

Dominique Lison (D)

Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Louvain centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 57, 1200, Brussels, Belgium. Electronic address: dominique.lison@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH